Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
OncoOne Targets Cancer-Related Isoform, OxMIF, In Multiple Ways
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.
Pipeline Watch: First Approvals For Vadadustat, Daprodustat, In Japan
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
EC Approves Extended Invokana Indication On Renal Outcomes In DKD
Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.
Need a specific report? 1000+ reports available
Buy Reports